Therefore, correction of hypophosphatemia in the face of residual FGF23 elevations is insufficient to correct the bone phenotype associated with ARHR in the long term and the residual bone phenotype might be due to persistent FGF23 elevations and/or DMP1 deficiency. This evidence concerns the gene DMP1 and hyperinsulinemic hypoglycemia, familial, 4.